GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound F [WO2021216671A1] | example 5A [US20210330651A1] | ZNc5
Compound class:
Synthetic organic
Comment: ZN-c5 was developed as an orally bioavailable selective estrogen receptor degrader (SERD) [1], for potential to treat breast cancer brain metastases. The core structure of ZN-c5 was used in the design of compounds with improved brain penetration and in vitro and in vivo efficacy, such as compound 5 [PMID: 40393772] [3].
|
|
No information available. |
Summary of Clinical Use ![]() |
Clinical development of ZN-c5 was discontinued in 2022. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03560531 | A Study of ZN-c5 in Subjects With Breast Cancer | Phase 1/Phase 2 Interventional | Zeno Alpha Inc. |